1. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
- Author
-
Wang, Li-Mei, Yang, Qi-Hua, Zhang, Lei, Liu, Sheng-Yun, Zhang, Pan-Pan, Zhang, Xin, Liu, Xiao-Jun, Han, Li-Shuai, and Li, Tian-Fang
- Subjects
- *
THERAPEUTIC use of immunoglobulins , *DISEASE progression , *IMMUNOGLOBULINS , *INTRAVENOUS therapy , *DERMATOMYOSITIS , *SCIENTIFIC observation , *INTERSTITIAL lung diseases , *RETROSPECTIVE studies , *MANN Whitney U Test , *FISHER exact test , *IMMUNOSUPPRESSION , *TREATMENT effectiveness , *T-test (Statistics) , *DESCRIPTIVE statistics , *CHI-squared test , *KAPLAN-Meier estimator , *DATA analysis software - Abstract
Objective Rapidly progressive interstitial lung disease (RP-ILD) in DM patients positive for anti-melanoma differentiation-associated gene 5 (anti-MDA5) autoantibody (MDA5-DM) often have a poor prognosis, frequently fatal. As there is a scarcity of data regarding the effect of intravenous immunoglobulin (IVIG) on RP-ILD in MDA5-DM patients (MDA5-RPILD), we conducted this study to determine the efficacy of a IVIG add-on initial treatment. Methods Patients with newly-onset MDA5-RPILD from September 2018 to June 2020 were retrospectively reviewed for 6 months in the First Affiliated Hospital of Zhengzhou University. They were divided into two groups: IVIG and non-IVIG groups. The major measurement of treatment outcome was the difference in the mortality in 3-month and 6-month between two group patients. Other relevant indicators were also recorded, including the incidence of infection, the dosages of GCs, the remission rate and the variables in laboratory data. Results The IVIG group (n = 31) showed significantly lower 6-month mortality rate than the non-IVIG group (n = 17) (22.6% vs 52.9%; P =0.033). The IVIG group patients had a higher remission rate at 3 months (71.0% vs 41.2%; P =0.044). Gradual reduction was observed in the first 3 months with regard to the titre of anti-MDA5 autoantibody, the serum level of ferritin and the ground glass opacification GGO scores. Conclusion IVIG adjunct therapy is a very effective first-line treatment for patients with MDA5-RPILD. IVIG may increase the survival and remission rate by lowering ferritin concentration, anti-MDA5 titre and GGO score. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF